Novo Nordisk A/S reported 18.44B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Bausch Health Companies USD 1.73B 593M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Merck USD 8.01B 622M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Novo Nordisk 38.94B 18.08B Mar/2025
Novo Nordisk A/S 18.44B 5.78B Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Sanofi 15.36B 7.37B Jun/2025
Supernus Pharmaceuticals USD 144.71M 28.86M Jun/2025